$11.49

-0.01 (-0.09%)

7/24/2008 10:10 AM

Cardiome Pharma Corp. (USA) (CRME)

CAPS Rating:

Life sciences company focused on developing proprietary drugs to treat or prevent cardiovascular diseases. Current efforts are focused on the treatment of atrial arrhythmias and congestive heart failure.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating CRME

Add Stock to Watchlist

What the Community Thinks

Total Members

85 Outperforms

19 Underperforms

All-Stars

29 Outperforms

10 Underperforms

Wall Street

2 Outperforms

0 Underperforms

Members bullish on CRME are also bullish on:

Members bearish on CRME are also bearish on:

Ticker Tags

Drug Manufacturers - Other (105), Micro Cap (4824)
Suggest a tag

Cardiome Pharma Corp. (USA) At A Glance

Current Price:	$11.49
Last Trade Time:	7/24/2008 10:10 AM
Open:	$11.57
Previous Close:	$11.50
Daily Range:	$11.36 - $11.74
52-Week Range:	$5.78 - $12.62
Volume:	132,069
Market Cap:	$733.24M
P/E Ratio:	0.00
Compare Our Special Broker Offers!

Stock Trends

CRME VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for CRME

Movers roundup: Cardiome Pharma, Pactiv
7/14/2008 2:17:00 PM - AP
Cardiome shares surge on positive heart drug data
7/14/2008 12:09:00 PM - AP
Summaries of Senate financial disclosure forms
6/13/2008 12:15:00 PM - AP

More Headlines...

Top Bull Pitch

Recs

1 Cardiome Pharma Corp. (USA) (CRME)

Avatar dividendsrg8t85 (51.15) Submitted: 1/08/08 3:56 PM

Vernakalant (IV) is almost a lock for FDA approval. It is the first drug of its type to hit the market in eight years.

The death in the study had NOTHING to do with the drug and if people, including analysts, would read the entire report instead of the front page they would...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1 Cardiome Pharma Corp. (USA) (CRME)

Avatar snark43 (< 20) Submitted: 12/08/07 5:28 AM

A one drug company with a negative FDA panel recomendation = NO approval and a plummeting price
The Phase III had a fatal incident and and was not even conducted with the most at risk (and most probable potential customer). In light of the FDA's recent reticence to approve Anything, this dog is cer...More

Replies: 0 | Reply | Permalink

CAPS Members

Show Me:

Sort by:

picks per page. CHANGE

Results 1 - 5 of 23 : 1 2 3 4 5 Next »

Recs 0 (CRME) Vavoom11 (99.74) Submitted: 7/14/08 11:43 AM : Start Price: $10.67 CRME Score: -4.63 short the pop! Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (CRME) cashsage (< 20) Submitted: 7/03/08 5:01 PM : Start Price: $8.65 CRME Score: -32.73 CRME is one of the companies with a too high valuation compared to its sales potential. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (CRME) JonAtkins57 (24.49) Submitted: 6/30/08 1:50 PM : Start Price: $8.86 CRME Score: -30.51 Market Cap > 100M and < 1B Gross Margin % < -10 Net Profit Margin % < -10 EPS < -1 Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (CRME) biovestor (37.96) Submitted: 6/30/08 10:26 AM : Start Price: $8.63 CRME Score: 33.99 Still waiting on FDA ruling for Kynapid, which should be approved plus oral form of the drug with more commercial potential and continued clinical development to move the shares higher. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (CRME) WhenOppsKnock (< 20) Submitted: 4/16/08 10:22 PM : Start Price: $7.10 CRME Score: 68.83 The IV version of its anti-fib heart drug, Kynapid (vernakalant hydrochloride), was recommended for approval with a 6-2 vote by an FDA advisory committee in December 2007. No action letter was delivered by the FDA to either Cardiome or its partner, Astellas Pharmaceuticals by the expected action date of January 19, 2008. However the FDA had requested more time to review the NDA. It has been assumed that 60 days (previously announced by the FDA as the new expected delay for the FDA on certain non-critical drugs) would be enough time to determine the approval status of the drug. However, at 60 days, no new news has been announced either by the FDA or by Cardiome or by its partner Astellas. Earlier in the week, Amgen announced that the FDA was pushing back its review of romiplostim by three months -- from an April 23 PDUFA date to July 23. The FDA has been constantly delaying its review of nearly all drugs in the first quarter, so Amgen had probably already guessed that some sort of announcement like this was coming. Therefore, assuming a possible 3-month delay by the FDA is to be expected for a drug approval beyond the standard approval timeframe, the time for a decision from the FDA on Kynapid nears. Assuming Kynapid will be reviewed timely by the FDA within a 90-day delay window, that would mean that the company should hear from the FDA by Saturday, April 19, 2008 (90th day), or by Monday, April 21, 2008 (92 days, or exactly 3 months). Therefore, an announcement is forthcoming either Thurday or Friday this week, or Monday or Tuesday next week. Very good probability of an approval of the $800 million to $1.3 billion per year IV version of the drug. Cardiome holds all rights to produce this drug outside of the US and is partnered with Astellas in the US. The oral version of the drug, is wholly owned by Cardiome within and outside of the US and Canada, and is in late Stage 2b trials. The market for the oral version of the drug is much greater ($1.3 billion - $1.8 billion per year). Recent early results of the Stage 3b drug trials are very positive. And Canadian approval could come any day now (early May 2008). Lastly, the company says it is up for possibly sale or partnership as it proceeds with late-stage trials of its oral version of the anti-fib heart drug. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Results 1 - 5 of 23 : 1 2 3 4 5 Next »

Wall Street

Results 1 - 2 of 2

picks per page. CHANGE

Top Pick	Member Name	Member Rating	Start Date	Call	Time Frame	Start Price	Stock Gain	S&P Gain	Score	Pitch
	TrackWachovia	79.92	03/20/08		NS	$8.10	+42.69%	-1.62%	+44.31
	TrackBearStearns	90.95	02/23/07		NS	$11.50	+0.50%	-12.21%	+12.71

Results 1 - 2 of 2

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.